| Literature DB >> 28068976 |
Onusa Thamsermsang1,2, Pravit Akarasereenont1,2, Tawee Laohapand2, Uraiwan Panich3.
Abstract
BACKGROUND: Pain is the main symptom of most musculoskeletal disorders and can be caused by inflammation in association with oxidative stress. Thai herbal Sahatsatara formula (STF), a polyherbal formula, has been traditionally used for relieving muscle pain and limb numbness. This study aimed to investigate biologically active compounds of STF and its pharmacological effects related to antioxidant and anti-inflammatory activities.Entities:
Keywords: Antioxidant; Gene expression profile; Inflammation; Thai herbal Sahatsatara formula; Thai herbal medicine
Mesh:
Substances:
Year: 2017 PMID: 28068976 PMCID: PMC5223377 DOI: 10.1186/s12906-016-1515-0
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
The percentage yields and IC30 values of free radical scavenging activities of STF extracts, its components and active compounds were obtained from DPPH assay and represented as Mean ± SEM. in triplicate experiments. IC30 values indicated concentrations of the test compounds required to scavenge DPPH radical by 30%
| No. | Material name | Part of usage | Percentage of components in formula (W/W)a | % yields (W/W)a | DPPH assay IC30 value (μg/mL) |
|---|---|---|---|---|---|
| 1 | L-ascorbic acid | - | - | - | 3.32 ± 0.22 |
| 2 | Piperine | - | - | - | >120 |
| 3 | Gallic acid | - | - | - | 8.04 ± 0.94 |
| 4 | STF formula | - | - | 19.78 | 19.62 ± 1.13 |
| 5 | 1,7, 7 – trimethylbicyclo (2.2.1) heptan −2- one (analytical camphor) | crystal | 1.40 | - | >120 |
| 6 |
| root | 8.80 | 1.73 | >120 |
| 7 |
| seed | 1.00 | 2.82 | >120 |
| 8 |
| root | 0.50 | 6.83 | >120 |
| 9 |
| root | 8.00 | 0.74 | 90.86 ± 16.96 |
| 10 |
| stem | 4.80 | 2.30 | 98.47 ± 4.81 |
| 11 |
| seed | 0.80 | 6.26 | 75.67 ± 11.63 |
| 12 |
| gum | 1.00 | 27.89 | >120 |
| 13 |
| seed | 1.10 | 7.83 | 49.43 ± 5.42 |
| 14 |
| stem | 0.80 | 1.49 | 25.17 ± 2.34 |
| 15 |
| fruit | 1.30 | 1.01 | 19.99 ± 1.17 |
| 16 |
| mace | 1.20 | 2.02 | 31.35 ± 3.13 |
| 17 |
| seed | 0.70 | 9.21 | >120 |
| 18 |
| root | 0.60 | 11.09 | 65.57 ± 8.81 |
| 19 |
| root | 0.40 | 7.70 | 84.96 ± 1.18 |
| 20 |
| seed | 0.90 | 5.40 | 78.54 ± 7.47 |
| 21 |
| fruit | 24.00 | 0.03 | >120 |
| 22 |
| fruit | 9.60 | 6.03 | >120 |
| 23 |
| root | 22.40 | 2.30 | 72.88 ± 6.84 |
| 24 |
| fruit | 10.40 | 28.29 | 5.14 ± 0.52 |
| 25 |
| gall | 0.30 | 8.83 | 2.35 ± 0.18 |
a(W/W) = gram unit
Fig. 1The HPLC fingerprints of phenolic compounds (a) and piperine (PP) (b) in STF extracts. Peak details; 1: kojic acid (RT: 6.103 min); 2: gallic acid (GA) (RT: 6.940 min); 3: caffeic acid (RT: 10.211 min); 4: vanellic acid (RT: 10.433 min); 5: p-coumaric acid (RT: 11.524 min); 6: ferulic acid (RT: 12.039 min)
Fig. 2Cytotoxicity of STF extracts (a), Piperine (PP) (b), Gallic acid (GA) (c), Indomethacin (d), IL-1β (e), ETOH80% (f) and DMSO (g) on NHDFs viability. The results were obtained from at least triplicate experiments, One-Way ANOVA (Dunnett’s post hoc test) was used to determine statistical significance and the data are represented as Mean ± SD. *P <0.05; **P <0.01; ***P <0.001 compared with control group
Fig. 3The effects of STF extracts and its active compounds on ROS formation was assessed by DCFDA-flow cytometry. IL-1β significantly enhanced ROS formation in a dose-dependent manner in IL-1β-treated NHDFs (a). The pretreatment of STF extracts (b), GA (c) and PP (d) can attenuate IL-1β-induced intracellular ROS levels whereas, treatment with each compound alone (b-d) and vehicle reagents (ETOH 80%) (e) didn’t affect ROS generation. DCFDA intensity data were presented as Mean ± SD at least three experiments. The statistical significant between control and IL-1β-treated cells was evaluated by Unpaired t-test and between IL-1β-treated and test compound–treated cells was assessed by one-way ANOVA followed by Dunnett’s post hoc test. **P < 0.01, *** P < 0.001 compared with control. # P < 0.05, ## P < 0.01 and ### P < 0.001 compared with IL-1β-treated cells
Fig. 4The differential expression of genes in NHDFs treated with IL-1β when compared with non-treated cells. The significantly altered genes (30 down-regulated and 54 up-regulated) induced by IL-1β were indicated by yellow dots and red dots, respectively (a). The Gene Ontology (GO) classification of 84 altered genes was performed using PANTHER classification system analysis (b).
List of significantly up-regulated genes in IL-1β-treated NHDFs using PANTHER pathway enrichment analysis. P < 0.05 was considered statistically significant
| No. | Pathway (PANTHER pathway ID) | Gene Symbol | Protein class |
|
|---|---|---|---|---|
| 1 | CCKR signaling map | BIRC3 | protease inhibitor | 2.17E-02 |
| CXCL1 | chemokine | |||
| CXCL2 | chemokine | |||
| NFKBIA | phospholipase | |||
| IL-8 | chemokine | |||
| 2 | Interleukin signaling pathway | IL-6 | interleukin superfamily | 3.78E-02 |
| IL-8 | chemokine |
The summery of 22 target genes involved in transactivation of NF-кB induced by IL-1β in NHDFs. All gene description and functional annotation were referred from PANTHER and NCBI databases
| Group | Gene symbol | Description/Function |
|---|---|---|
| Transcription factor and their modulators | CEBPD | CCAAT/Enhancer Binding Protein (C/EBP), Delta /regulation of genes involved in immune and inflammatory responses (macrophage) |
| IRF1 | Interferon Regulatory Factor 1/ an activator of interferons alpha and beta transcription, regulations of apoptosis and tumor-suppression | |
| NFKB1 | Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells 1/ sequence-specific DNA binding transcription factor activity and transcription factor binding | |
| NFKBIA (IκBα) | Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells Inhibitor, Alpha / inhibits the activity of dimeric NF-kappa-B/REL complexes | |
| NFKBIZ (IκBZ) | Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells Inhibitor, Zeta / a member of the ankyrin-repeat family, produce IL6 secretion induced by lipopolysaccharide. | |
| TNFAIP3 | Tumor Necrosis Factor, Alpha-Induced Protein3/ ubiquitin-protein transferase activity and inhibit NF-kappa B activation as well as TNF-mediated apoptosis | |
| Chemokines and Interleukins | CCL2 | Chemokine (C-C Motif) Ligand 2/ A member of the CC subfamily contains chemotactic activity for monocytes and basophils |
| CXCL1 | Chemokine (C-X-C Motif) Ligand 1 (Melanoma Growth Stimulating Activity, Alpha)/ chemotactic activity for neutrophil | |
| CXCL2 | Chemokine (C-X-C Motif) Ligand 2/ produced by activated monocytes and neutrophils and expressed at sites of inflammation | |
| CXCL6 | Chemokine (C-X-C Motif) Ligand 6 /chemotactic activity for neutrophil | |
| IL-6 | Interleukin 6/ cytokine activity and interleukin-6 receptor, relation with B-cells, lymphocyte and monocyte differentiation,inflammation | |
| IL-8 | Chemokine (C-X-C Motif) Ligand 8/ the major mediators of the inflammatory response, chemotactic activity that attracts neutrophils, basophils and T-cell | |
| Immunoreceptors | CD83 | CD83 Molecule/ an antigen presentation or the cellular interactions that follow lymphocyte activation |
| NOD2 | Nucleotide-Binding Oligomerization Domain Containing 2/ protein kinase binding and peptidoglycan binding. | |
| CFB | Complement Factor B / serine-type endopeptidase activity and complement binding | |
| Cell adhesion molecules and receptors | ICAM1 | Intercellular Adhesion Molecule 1/ a cell surface glycoprotein |
| NINJ1 | Ninjurin 1/ Homophilic cell adhesion molecule | |
| VCAM1 | Vascular Cell Adhesion Molecule 1/ integrin binding and primary amine oxidase activity | |
| Stress response genes | SOD2 | Superoxide Dismutase 2, Mitochondrial/ deSTFoys superoxide anions |
| Enzymes | PTGES | Prostaglandin E Synthase / catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2) |
| Early response genes | TNFAIP2 | Tumor Necrosis Factor, Alpha-Induced Protein 2/ a mediator of inflammation and angiogenesis |
| Miscellaneous | TFPI2 | Tissue Factor Pathway Inhibitor 2/ serine-type endopeptidase inhibitor activity and extracellular matrix STFuctural constituent |
Fig. 5The heat map of target genes of 54 up-regulated genes (a) and 30 down-regulated genes (b) showed differential pattern of gene expressions in NHDFs pretreated with test compounds prior to IL-1β (1 ng/mL) challenge. Column details: A: indomethacin (50 μM) + IL-1β; B: GA 3 μg/mL+ IL-1β; C: PP 30 μg/mL+ IL-1β and D: STF 3 μg/mL+ IL-1β
Fig. 6The difference of target gene expression patterns of test compounds in NHDFs induced by IL-1β 1 ng/mL for 4 h (a-i); (a) Indomethacin 50 μM,(b) PP 1 μg/mL,(c) PP 30 μg/mL, (d) GA 0.3 μg/mL, (e) GA 1 μg/mL and (f) GA 3 μg/mL, (g) STF 3 μg/mL, (h) STF 10 μg/mL, (i) STF 30 μg/mL